BCL9 pseudogene 1 (BCL9P1)

BCL9 pseudogene 1 (BCL9P1) is a pseudogene related to the BCL9 gene, which is a key transcriptional co-activator in the Wnt/β-catenin pathway[3][4][1]. However, BCL9P1 itself is not known to be expressed as a protein, to have any functional role, or to serve as a therapeutic target. Pseudogenes are typically remnants of genes that may share sequence similarity to their functional counterparts but lack coding potential or regulatory activity. No biological functions, disease roles, or drug interactions are established for BCL9P1. Therefore, BCL9P1 is not considered a valid molecular target in biomedical research or therapeutic applications. If you intended to inquire about BCL9 (B-cell CLL/lymphoma 9 protein), it is an established transcriptional co-activator in Wnt signaling, involved in cancer and developmental processes[3][4][1]. BCL9, but not BCL9P1, would be considered a therapeutic target, especially in oncology research. There is something incorrect with this target for therapeutic purposes: BCL9P1 is not a functional target and generally would not be included in lists of druggable or therapeutic molecular targets. If you are seeking information about a therapeutically relevant target, BCL9 itself (not the pseudogene) should be considered.

Other names

BCL9P1BCL9PB-cell CLL/lymphoma 9 pseudogene 1BCL9-psi-1